Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?
2026-09-04 18:30
•Prosper Junior Bakiny •The Motley Fool
•• •• Axe Cap view
Vertex vs Regeneron: Biotech Battle with a Clear Local Angle
Vertex’s cystic fibrosis dominance makes it a safer bet than Regeneron’s riskier weight-loss play.
While biotech might feel distant from the JSE, there’s a useful local angle here through USD/ZAR. Vertex’s strong patent protection for cystic fibrosis drugs until the late 2030s means steady dollar cash flow, supporting a more stable USD/ZAR outlook. Regeneron’s fate feels tethered to weight-loss treatments, a crowded and unpredictable market segment. For investors eyeing South Africa, the rand tends to weaken when US growth uncertainties rise, which might happen if Regeneron stumbles. Vertex’s niche focus and proven track record mean lower execution risk, making it a better signal for a steady rand and measured exposure in offshore biotech. If US inflation surprises on the upside, rand weakness could overshadow any biotech gains, so that’s the main risk to weigh here. this is just our opinion and not financial advice
For rand-sensitive portfolios, buy Vertex via USD exposure and avoid Regeneron for now. Hedge downside in the rand with stronger rand pairs if global sentiment sours.
- VRTX
- REGN
- USD/ZAR
- US inflation surprises weaken rand more than expected
- Regeneron’s weight-loss drugs outperform, shifting biotech demand
6/10
The biotech industry is experiencing a strong rebound in 2026. While both Vertex Pharmaceuticals and Regeneron are attractive options, Vertex emerges as the better buy due to its stronger competitive advantage in cystic fibrosis drugs with patent protection until the late 2030s, diversified pipeline targeting high-need areas with less competition, and lower execution risk compared to Regeneron's dependence on weight-loss candidates and defending its Dupixent franchise against increasing competition.
Our take is based on reporting first published by The Motley Fool.